

## DIAGNOCURE ANNOUNCES FIRST QUARTER 2008 RESULTS

**QUEBEC CITY, March 5, 2008**— DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, announced a net loss of \$2,685,309 or \$0.06 per share for the first quarter ending January 31, 2008. These results are substantially in line with Management expectations. They reflect the beginning of DiagnoCure's U.S. initiatives in view of the upcoming launch of Previstage™ GCC, the Company's new colorectal cancer staging test. At the end of the quarter, cash, short-term investments and long-term investments stood at \$30,336,246, up from \$17,243,629 as at January 31, 2007. This increase is attributable to the net proceeds from the April 2007 financing.

### Highlights of the Quarter

In view of the significant progress made on Previstage™ GCC and the upcoming commercial launch, DiagnoCure signed an agreement, in December 2007, on a service lab located in West Chester, Pennsylvania. DiagnoCure Oncology Laboratories will offer, throughout the North American market, testing services under CLIA certification using Company's proprietary molecular tests.

Also in December 2007, Gen-Probe, to which DiagnoCure licensed its PCA3 marker in 2003, announced additions to its European sales and marketing team to support PCA3's continued commercialization development in that area.

In January 2008, the American Society of Clinical Oncology held its annual Gastrointestinal Cancers Symposium (ASCO GI). This event represented the perfect opportunity for DiagnoCure to introduce to the medical community the science behind Previstage™ GCC, the Company's new colorectal cancer staging test. Previstage™ GCC employs qRT-PCR technology, which has been shown to be up to 100,000-times more sensitive than traditional histopathology in detecting occult metastases. The staging test could therefore help physicians determine the most appropriate course of treatment for their colorectal cancer patients.

Finally, at the end of January, J.F. Bureau, CFA, joined DiagnoCure's executive team as Senior Vice President and Chief Financial Officer. Mr. Bureau's experience spans nearly twenty years on the North American and European financial markets.

### Results for the first quarter ended January 31, 2008

Total revenues for the first quarter of 2008 were \$491,455 compared with \$1,176,577 for the first quarter of 2007. In the first quarter of 2008, DiagnoCure had no revenue recognition of the continued calendar payments and research agreement from Gen-Probe compared with \$843,257 from the prior year first quarter. This decrease reflects the end of the revenue recognition from the continued calendar payments received from Gen-Probe which had been amortized over a 42-month period from the signing of the original license agreement. Royalty revenues from Gen-Probe were \$40,787 for the first quarter of 2008 compared to \$17,077 for the first quarter of 2007. Sales of DiagnoCure's non-invasive bladder cancer test, ImmunoCyt™ / uCyt+™, were \$79,688 for the first quarter of 2008 versus \$81,912 for the same period a year ago. Income from research and development contracts, predominantly with Gen-Probe, has decreased in 2008 by \$70,588 as specific PCA3-related contracted R&D projects are completed. Also in this quarter, DiagnoCure sold clinical samples to Gen-Probe, in support of their prostate cancer testing R&D, for an amount of \$35,550 compared with \$38,036 in the first quarter of 2007.

Interest income increased \$139,135 to \$335,430 for the first quarter of 2008 compared to \$196,295 for the first quarter of 2007. The increase is attributable to the interest generated on the net proceed of \$23,353,098 received from the April 2007 financing.

Cost of sales decreased \$14,672, from \$84,462 for the first quarter of 2007 to \$69,790 for the first quarter of 2008. This decrease is related to lower actual product sales, as noted above, for ImmunoCyt™ / uCyt+™ and sample sales.

Based on the above, for the first quarter of 2008, DiagnoCure recorded a net loss, before stock-based compensation and restructuring charges, of \$2,396,015 compared with \$1,089,570 for the same period of 2007. The net loss including stock based compensation and restructuring charges was \$2,685,309 or \$0.06 per share for the first quarter of 2008, compared with \$2,457,480, or \$0.07 per share, for the first quarter of 2007. These results were substantially in line with Management expectations and reflect activities undertaken during the quarter in line with the Company's plans and on-going commitment to develop high-value diagnostic tests for the detection and management of cancer. At the end of the quarter, cash, short-term investments and long-term investments stood at \$30,336,246, down from \$32,867,526 as at October 31, 2007. This decrease of \$2,531,280 is due to the use of cash to finance our operating activities and acquisitions for this quarter. Management is satisfied that it has adequate cash resources to execute its business plan in the near-term and mid-term.

#### Financial Data

	For the first quarter ended January 31	
	2008	2007
Sales	115,238	137,025
Revenue under research and license agreement	40,787	843,257
Interest	335,430	196,295
Total revenues	491,455	1,176,577
Cost of sales	69,790	84,462
Gross margin	421,665	1,092,115
Operating expenses (before stock-based compensation and restructuring charges)	2,817,680	2,181,685
Net loss before stock-based compensation and restructuring charges	( 2,396,015 )	( 1,089,570 )
Restructuring charges	---	912,685
Stock-based compensation	289,294	455,225
Net loss	( 2,685,309 )	( 2,457,480 )
Basic and diluted net loss per share	( 0.06 )	( 0.07 )
Weighted average number of common shares outstanding	41,720,130	34,462,537

#### Consolidated Balance Sheets

	As at January 31	
	2008	2007
Cash, cash equivalents, temporary and long-term investments	30,336,246	17,243,629
Total assets	41,955,296	19,897,379
Shareholders' equity	37,797,840	17,737,429

## **About DiagnoCure**

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure is currently preparing to launch the Previstage™ GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. In 2003, the Company entered into a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation test for PCA3, DiagnoCure's proprietary molecular marker highly specific to prostate cancer. The test is now available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA™ PCA3 *in vitro* assay. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from both academic and commercial institutions. For more information, visit [www.diagnocure.com](http://www.diagnocure.com).

## **Forward-looking statements**

This release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward-looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

-30-

### **Contacts:**

#### **Investors**

**DiagnoCure Inc.**

J.F. Bureau, CFA

Sr. Vice President and CFO

(418) 527-6100

[communications@diagnocure.com](mailto:communications@diagnocure.com)

#### **Media**

**Jean-Pierre Trudel & Associates**

Jean-Pierre Trudel

(514) 347-6111

[jp.trudel@videotron.ca](mailto:jp.trudel@videotron.ca)